SCHEMBL7674446

SCHEMBL7674446

Cc1cc(C(C)C(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.60
ABCB11 O95342 1/20 0.60
CYP1A2 P05177 4/20 0.53
TSHR P16473 3/20 0.53
LMNA P02545 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
ALDH1A1 P00352 1/20 0.53
MAPT P10636 4/20 0.48
CYP2C9 P11712 3/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C19 P33261 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SRD5A2 P31213 1/20 0.40
HTT P42858 3/20 0.39
NPSR1 Q6W5P4 2/20 0.38
POLB P06746 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11714056 0.90 PTGS2 (0.51) PTGS2ABCB11CYP1A2TSHRLMNA
SCHEMBL2739333 0.89 ABCB11 (0.63) PTGS2ABCB11CYP1A2TSHRLMNA
SCHEMBL7676990 0.89 PTGS2 (0.46) PTGS2ABCB11CYP1A2TSHRLMNA
SCHEMBL7674668 0.87 PTGS2 (0.49) PTGS2ABCB11CYP1A2TSHRLMNA
SCHEMBL7678100 0.87 ABCB11 (0.58) PTGS2ABCB11CYP1A2TSHRLMNA
SCHEMBL7681922 0.86 PTGS2 (0.44) PTGS2ABCB11CYP1A2TSHRLMNA
SCHEMBL7681936 0.85 PTGS2 (0.44) PTGS2ABCB11CYP1A2TSHRLMNA
SCHEMBL11717017 0.85 PTGS2 (0.46) PTGS2ABCB11CYP1A2TSHRLMNA
SCHEMBL7680616 0.83 SRD5A2 (0.44) PTGS2ABCB11CYP1A2TSHRLMNA
SCHEMBL7674658 0.83 PTGS2 (0.41) PTGS2ABCB11CYP1A2TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed
US-4070368-A ACYLATION, DECARBOXYLATION MCNEIL LABORATORIES, INCORPORATED (US) 1978-01-24 US disclosed
US-4011332-A RODENTICIDE BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) 1977-03-08 US disclosed
US-3952012-A MULTISTAGE MCNEIL LABORATORIES, INCORPORATED (US) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A PTGS2 887/4885ABCB11 2317/4885CYP1A2 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.